The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Temsirolimus (T) in patients (pts) with colorectal cancer (CRC) with PIK3CA mutation: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.
 
Jean L. Grem
No Relationships to Disclose
 
Michael Rothe
Employment - Emmes
 
Pam K. Mangat
No Relationships to Disclose
 
Elizabeth Garrett-Mayer
Consulting or Advisory Role - Deciphera
 
Maged F. Khalil
No Relationships to Disclose
 
Shane O. Rogosin
Stock and Other Ownership Interests - Abbott Laboratories (I)
 
John Stuart Salmon
Stock and Other Ownership Interests - Abbvie; Agenus; Agios; Bluebird Bio; Briacell; Briacell; Bristol-Myers Squibb; Cardiff Oncology
Research Funding - Bayer (Inst)
 
Timothy Lewis Cannon
Honoraria - AstraZeneca; Deciphera
Consulting or Advisory Role - Loxo; Navican
Other Relationship - Navican/ Intermountain Healthcare
 
Gina N. Grantham
No Relationships to Disclose
 
Susan Halabi
Employment - ASCO
 
Richard L. Schilsky
Leadership - Clarified Precision Medicine
Consulting or Advisory Role - Bryologyx; Cellworks; EQRx; Illumina; Scandion Oncology
Research Funding - AstraZeneca (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Lilly (Inst); Merck (Inst); Pfizer (Inst); Seagen (Inst)